EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-Based Therapeutics in Autoimmune Diseases: Mechanisms, Challenges, and Future Perspectives

Naim Mahroum iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Naim Mahroum. Beteiligte Einrichtung: International School of Medicine, Istanbul Medipol University, Kavacık, Göztepe Mah, Atatürk Cd. No: 40, Beykoz, 34810 Istanbul, Türkiye. Hauptthemen laut MEDLINE: Autoimmune Diseases, Antibodies, Monoclonal, Immunotherapy. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune diseases encompass nearly 100 distinct conditions characterized by dysregulated immune responses against self-antigens, resulting in tissue damage, chronic inflammation, and substantial morbidity. Over recent decades, the global burden of autoimmune diseases has increased, while their therapeutic management has undergone a paradigm shift from broad, nonspecific immunosuppression toward targeted biologic therapies. Among these, antibody-based therapeutics, including monoclonal antibodies targeting cytokines, cell-surface molecules, and co-stimulatory pathways, have transformed the treatment of numerous systemic and organ-specific autoimmune disorders. Nevertheless, important challenges remain, including primary non-response, secondary loss of efficacy related to immunogenicity or disease adaptation, increased susceptibility to infections, and mechanistic redundancy among therapeutic targets. This review provides a comprehensive overview of the cellular and molecular mechanisms underlying antibody-based therapies, summarizes major therapeutic target classes across autoimmune diseases, and examines their clinical and mechanistic limitations. Emerging therapeutic platforms, including bispecific antibodies, antibody–drug conjugates (ADCs), novel Fc-engineering, and cellular approaches such as CD19-targeted chimeric antigen receptor (CAR)-T therapy, are also discussed. Finally, antigen-specific immunotherapies designed to restore antigen-specific immune tolerance while preserving systemic host defense are explored. These approaches may represent an important next frontier in the treatment of autoimmune diseases, moving beyond broad systemic immune modulation toward more selective and durable immune control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesAntibodies, MonoclonalImmunotherapyHumansAnimalsImmunoconjugatesAntibodies, BispecificImmune Tolerance

Stichwörter der Autor:innen

antibody-based treatmentautoimmunityimmunomodulationimmunosuppressantsmonoclonal antibodies

Substanzen

Antibodies, MonoclonalImmunoconjugatesAntibodies, Bispecific

Autor:innen und Institutionen

  • International School of Medicine, Istanbul Medipol University, Kavacık, Göztepe Mah, Atatürk Cd. No: 40, Beykoz, 34810 Istanbul, Türkiye.

ORCID-Profile: Naim Mahroum

Zitieren

APA

Mahroum, N. (2026). Antibody-Based Therapeutics in Autoimmune Diseases: Mechanisms, Challenges, and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188030

Vancouver

Mahroum N. Antibody-Based Therapeutics in Autoimmune Diseases: Mechanisms, Challenges, and Future Perspectives. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188030

BibTeX
@article{Mahroum2026,
  author = {Mahroum, Naim},
  title = {Antibody-Based Therapeutics in Autoimmune Diseases: Mechanisms, Challenges, and Future Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188030}
}
Kostenlos starten →